Literature DB >> 31660732

Molecular Mechanism and Kinetics of Amyloid-β42 Aggregate Formation: A Simulation Study.

Viet Hoang Man1, Xibing He1, Beihong Ji1, Shuhan Liu1, Xiang-Qun Xie1, Junmei Wang1.   

Abstract

As an important neuropathological hallmark of Alzheimer's disease (AD), the oligomerization of amyloid-β (Aβ) peptides has been intensively investigated in both theoretical and experimental studies. However, the oligomerization space in terms of the kinetics, molecular mechanism, and oligomer structures remains mysterious to us. An equation that can quantitatively describe the time it takes for Aβ oligomers to appear in the human brain at a given Aβ monomer concentration is extremely vital for us to understand the development and disease progression of AD. In this study, we utilized molecular dynamics (MD) simulations to investigate the oligomerization of Aβ42 peptides at five different monomer concentrations. We have elucidated the formation pathways of Aβ tetramers, characterized the oligomer structures, estimated the oligomerization time for Aβ dimers, trimers, and tetramers, and for the first-time derived equations that could quantitatively describe the relationship between the oligomerization time and the monomer concentration. Applying these equations, our prediction of oligomerization time agrees well with the experimental and clinical findings, in spite of the limitations of our oligomerization simulations. We have found that the Aβ oligomerization time depends on the monomer concentration by a power of -2.4. The newly established equations will enable us to quantitatively estimate the risk score of AD, which is a function of age. Moreover, we have identified the most dominant pathway of forming Aβ tetramers, probably the most important and toxic Aβ oligomer. Our results have shown that the structures of Aβ42 dimer, trimer, and tetramer, which are distinguishable from each other, depend on the monomer concentration at which the oligomers form. Representative oligomer structures, which can serve as potential drug targets, have been identified by clustering analysis. The MD sampling adequacy has been validated by the excellent agreement between the calculated and measured collisional cross section (CCS) parameters (the prediction errors are within 2%). In a conclusion, this study provides the kinetics and structure basis for developing inhibitors to decelerate the Aβ oligomerization process.

Entities:  

Keywords:  Alzheimer’s disease; amyloid-beta; concentration; equation; oligomerization; oligomers

Year:  2019        PMID: 31660732      PMCID: PMC7336531          DOI: 10.1021/acschemneuro.9b00473

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  56 in total

1.  Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis.

Authors:  M D Kirkitadze; M M Condron; D B Teplow
Journal:  J Mol Biol       Date:  2001-10-05       Impact factor: 5.469

2.  3D structure of Alzheimer's amyloid-beta(1-42) fibrils.

Authors:  Thorsten Lührs; Christiane Ritter; Marc Adrian; Dominique Riek-Loher; Bernd Bohrmann; Heinz Döbeli; David Schubert; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

3.  Aggregation rate of amyloid beta peptide is controlled by beta-content in monomeric state.

Authors:  Tran Thi Minh Thu; Nguyen Truong Co; Ly Anh Tu; Mai Suan Li
Journal:  J Chem Phys       Date:  2019-06-14       Impact factor: 3.488

4.  Conformational Ensembles of the Wild-Type and S8C Aβ1-42 Dimers.

Authors:  Viet Hoang Man; Phuong H Nguyen; Philippe Derreumaux
Journal:  J Phys Chem B       Date:  2017-03-10       Impact factor: 2.991

5.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Pathways of Amyloid-β Aggregation Depend on Oligomer Shape.

Authors:  Bogdan Barz; Qinghua Liao; Birgit Strodel
Journal:  J Am Chem Soc       Date:  2017-12-28       Impact factor: 15.419

7.  Alzheimer's beta-peptide oligomer formation at physiologic concentrations.

Authors:  Harry LeVine
Journal:  Anal Biochem       Date:  2004-12-01       Impact factor: 3.365

8.  Membrane-bound tetramer and trimer Aβ oligomeric species correlate with toxicity towards cultured neurons.

Authors:  Metta K Jana; Roberto Cappai; Chi L L Pham; Giuseppe D Ciccotosto
Journal:  J Neurochem       Date:  2016-02       Impact factor: 5.372

9.  High-resolution NMR characterization of low abundance oligomers of amyloid-β without purification.

Authors:  Samuel A Kotler; Jeffrey R Brender; Subramanian Vivekanandan; Yuta Suzuki; Kazutoshi Yamamoto; Martine Monette; Janarthanan Krishnamoorthy; Patrick Walsh; Meagan Cauble; Mark M Banaszak Holl; E Neil G Marsh; Ayyalusamy Ramamoorthy
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

10.  Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism.

Authors:  Samuel I A Cohen; Sara Linse; Leila M Luheshi; Erik Hellstrand; Duncan A White; Luke Rajah; Daniel E Otzen; Michele Vendruscolo; Christopher M Dobson; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-23       Impact factor: 11.205

View more
  1 in total

Review 1.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.